Pfizer Inc. has announced positive topline results from the Phase 3 BASIS study evaluating HYMPAVZI™ (marstacimab) for adults and adolescents with hemophilia A or B with inhibitors. The study demonstrated a statistically significant and clinically meaningful reduction in annualized bleeding rate compared to on-demand treatment in patients aged 12 and older. HYMPAVZI, administered as a once-weekly subcutaneous injection, showed a generally well-tolerated safety profile. Results from the full Phase 3 dataset are currently being analyzed, with additional data to be presented at upcoming medical meetings. Pfizer intends to discuss these findings with regulatory authorities to initiate filings for HYMPAVZI's approval for use in patients with hemophilia with inhibitors.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。